Price Change to Note: It Seems PhaseRx Inc Will Go Down. Just Reaches Yearly Low

Price Change to Note: It Seems PhaseRx Inc Will Go Down. Just Reaches Yearly Low

The stock of PhaseRx Inc (NASDAQ:PZRX) hit a new 52-week low and has $2.36 target or 12.00% below today’s $2.68 share price. The 5 months bearish chart indicates high risk for the $35.47 million company. The 1-year low was reported on Oct, 3 by Barchart.com. If the $2.36 price target is reached, the company will be worth $4.26 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock increased 4.28% or $0.11 on October 3, hitting $2.68. About 280,085 shares traded hands or 2071.20% up from the average. PhaseRx Inc (NASDAQ:PZRX) has risen 6.00% since September 3, 2016 and is uptrending. It has underperformed by 6.22% the S&P500.

Analysts await PhaseRx Inc (NASDAQ:PZRX) to report earnings on November, 1. After $-0.59 actual EPS reported by PhaseRx Inc for the previous quarter, Wall Street now forecasts -66.10% EPS growth.

According to Zacks Investment Research, “PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash.”

More notable recent PhaseRx Inc (NASDAQ:PZRX) news were published by: Marketwatch.com which released: “PhaseRx Inc.” on May 18, 2016, also Prnewswire.com with their article: “PhaseRx to Present at the 2016 Aegis Growth Conference” published on September 14, 2016, Prnewswire.com published: “PhaseRx Appoints Peggy Phillips to Board of Directors” on August 22, 2016. More interesting news about PhaseRx Inc (NASDAQ:PZRX) were released by: Prnewswire.com and their article: “PhaseRx Announces Pricing of Initial Public Offering” published on May 18, 2016 as well as Prnewswire.com‘s news article titled: “PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases” with publication date: June 21, 2016.

PZRX Company Profile

PhaseRx, Inc. is a preclinical biopharmaceutical company. The Firm develops a portfolio of products for the treatment of inherited enzyme deficiencies in the liver, using intracellular enzyme replacement therapy, i-ERT. The Company’s i-estrogen replacement therapy (ERT) approach is enabled by its Hybrid messenger ribonucleic acid (RNA), or messenger ribonucleic acid (mRNA), Technology platform, which allows synthesis of the missing enzyme inside the cell. The Company’s product portfolio consists of approximately three urea cycle disorders, which include ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase (ASL) deficiency and argininosuccinate synthetase (ASS1) deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment